Keros Therapeutics (KROS) Tops Q1 EPS by 481c

Keros Therapeutics (NASDAQ: KROS) reported Q1 EPS of $3.62, $4.81 better than the analyst estimate of ($1.19). Revenue for the quarter came in at $211.25 million versus the consensus estimate of $1.26 million.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Femasys Inc. (FEMY) Misses Q2 EPS by 20c
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c